Hormonal prevention of hereditary breast cancer

Annals of the New York Academy of Sciences

Volumn 952, Issue , 2001, Pages 36-43

  Narod, Steven A ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

BRCA1; BRCA2 gene; Hereditary breast cancer; Hormonal prevention

Indexed keywords

ANTIESTROGEN; BRCA1 PROTEIN; BRCA2 PROTEIN; GONADORELIN AGONIST; GOSERELIN; ORAL CONTRACEPTIVE AGENT; TAMOXIFEN;

BREAST CANCER; BREAST FEEDING; CANCER HORMONE THERAPY; CANCER PREVENTION; CANCER RISK; CIGARETTE SMOKING; CONFERENCE PAPER; DISEASE PREDISPOSITION; DNA MODIFICATION; ENVIRONMENTAL FACTOR; FAMILIAL CANCER; FEMALE; GENE MUTATION; HETEROZYGOTE; HIGH RISK PATIENT; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; LONG TERM CARE; MATERNAL AGE; MENOPAUSE; ONCOGENE; OVARIECTOMY; PARITY;

EID: 0035680432     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2001.tb02726.x     Document Type: Conference Paper

References (35)

1. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families
2. Frequency of recurrent BRCA1 and BRCA2 mutations in 222 Ashkenazi Jewish breast cancer families
3. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families
4. Breast and ovarian cancer incidence in BRCA1 mutation carriers
5. BRCA-associated breast cancer in young women
6. Survival and tumour characteristics of breast cancer patients with germline mutations of BRCA1
7. The natural history of breast carcinoma. What have we learned from screening?
8. Canadian National Breast Screening Study; 1. Breast cancer detection and death rates among women aged 40-49 years
9. Germline BRCA1 mutations in an adverse prognostic factor in Ashkenazi Jewish women with breast cancer
10. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations
11. Familial invasive breast cancers: Worse outcome related to BRCA1 mutations
12. Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: Preliminary results
13. Comparison of breast magnetic resonance imaging, mammography and ultrasound for surveillance of women at high risk for hereditary breast cancer
14. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer
15. Prophylactic surgery in BRCA1/2 mutation carriers: Predictive factors and follow-up
16. Reduction in breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers
17. Reduction in breast cancer risk following bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers
18. Pregnancy increases the risk of early onset breast cancer in BRCA1 and BRCA2 carriers
19. The effect of smoking on breast cancer incidence in BRCA1 and BRCA2 carriers
20. Cigarette smoking increases risk for breast cancer in high-risk breast cancer families
21. Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking
22. Urinary estrogen metabolites and breast cancer: A case-control study
23. Changes in levels of urinary estrogen metabolites after oral indole-3-carbinol treatment in humans
24. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women?
25. Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer
26. Breast cancer and hormonal contraceptives: Collaborative re-analysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies
27. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer
28. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital Tamoxifen Randomised Chemoprevention Trial
29. Prevention of breast cancer with tamoxifen; preliminary findings from the Italian randomised trial among hysterectomised women
30. Tamoxifen for prevention of breast cancer; report of the National Surgical Adjuvant Breast and Bowel Project PI Study
31. Tamoxifen for early breast cancer: An overview of the randomized trials
32. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 carriers
33. Menopausal estrogen replacement therapy and breast cancer risk